Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psychiatric diseases

- PMLiVE

With Spiriva under pressure, Boehringer moves to bolster pipeline

Forges alliance with PureTech Health

- PMLiVE

Boehringer’s IL-36-targeting drug tackles rare form of psoriasis

Antibody would be first-in-class

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

Innovative approaches in the treatment of multiple sclerosis

Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.

Blue Latitude Health

- PMLiVE

In conversation with Pfizer’s Erik Nordkamp

Pfizer’s UK managing director and newly appointed ABPI President talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe

- PMLiVE

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?

Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Page & Page and Partners

- PMLiVE

Boehringer beefs up biologics capacity with €230m investment

New facility to focus on analytical and process development and manufacturing of biologics for trials.

EphMRA Annual Conference 2018

Visit us on stand number 20

Research Partnership

Boehringer partners with Bactevo on drug discovery

Bactevo will use its TIME platform to identify small molecule lead compounds

Boehringer Ingelheim headquarters

Boehringer partners with Bactevo on drug discovery

Bactevo will use its TIME platform to identify small molecule lead compounds

- PMLiVE

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Offers €15m upfront for the anti-SIRP-alpha antibody and €15m when it reaches phase I testing

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links